JNJ-64565111, a once-weekly GLP-1 and glucagon receptor dual agonist, showed encouraging weight loss but no improvement in glycaemic parameters in adults with type 2 diabetes and obesity [25]. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.